Company intelligence / Profile preview

Senlong Pharmaceutical

Ownership: Private
Employees: ~201
Development stage: Other

Overview

Senlong Pharmaceutical develops and commercializes herbal medicines with a focus on infectious diseases such as chronic hepatitis B. Its lead product, Anluohuaxian capsule, received approval in China in 2020 for chronic hepatitis B. The company also has related entities or subsidiaries involved in animal health and diagnostics. Zhuhai Senlo (Senlong) Biotech focuses on R&D and production of automatic biochemical analyzers for clinical laboratories. Beijing Senlong Pharmaceutical appears to be an active pharmaceutical manufacturer with $22 million revenue reported in 2024.

Therapeutic areas: Infectious DiseasesOther
Modalities: Herbal medicine
Industry: Biotech

Drug pipeline

5 assets

anluohuaxian

Unknown

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Senlong Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senlong Pharmaceutical.

Explore the full profile